How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 56.3 | 56.3 | 56.2 | 51.3 | 51.3 | 51.3 | -5.0 |
| Healthcare | 19.1 | 19.1 | 19.1 | 23.0 | 23.0 | 23.0 | +3.9 |
| Financial Services | 1.5 | 1.5 | 1.4 | 1.3 | 1.3 | 1.3 | -0.2 |
| Unclassified | 2.9 | 2.9 | 2.9 | · | · | · | -0.0 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 8.35% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| IPCALAB | Pharma | 7.81% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
| CIPLA | Pharma | 7.68% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| SAILIFE | Healthcare | 6.86% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| GLAND | Pharma | 6.26% | 9 | 8 | 6 | 6 | 4 | 0/2 | +38.5% |
| APOLLOHOSP | Healthcare | 4.81% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| COHANCE | Healthcare | 4.15% | 4 | 5 | 4 | 10 | 4 | 0/2 | +13.2% |
| LAURUSLABS | Pharma | 3.76% | 8 | 9 | 4 | 4 | 1 | 0/2 | +34.0% |
| VIJAYA | Pharma | 3.70% | 8 | 10 | 4 | 2 | 1 | 0/2 | +37.0% |
| PFIZER | Healthcare | 2.79% | 3 | 7 | 1 | 2 | 7 | 0/2 | -9.0% |
| CONCORDBIO | Pharma | 1.58% | 5 | 4 | 2 | 1 | 4 | 0/2 | +19.8% |
| EMCURE | Pharma | 1.51% | 8 | 10 | 5 | 5 | 3 | 0/2 | +9.8% |
| ICICIGI | Financial Services | 1.31% | 3 | 6 | 5 | 8 | 6 | 0/2 | -2.8% |
| ALKEM | Pharma | 0.62% | 9 | 8 | 8 | 10 | 6 | 1/2 | +0.5% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹198 (+98%), vs ₹169 for Nifty 500 (+69%) and ₹152 for Nifty 50 (+52%). Its relative-strength line ended at 130 vs Nifty 50 and 117 vs Nifty 500 — above 100, sustained outperformance.